Product Code: PHA1236
The global Rare Diseases market is projected to grow at a CAGR of 12.27% by 2033.
“The Rare Diseases Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Home-based Care Anticipated to Offer Lucrative Growth Prospects
There are unmet requirements for elderly, frail people with multiple diseases, but many support services today focus on patients with rare or ultra-rare diseases. In addition, there are numerous chronic conditions present in sizable patient communities, even in younger age groups. Expanding home-based healthcare services could therefore have positive effects on bigger patient populations and health systems.
Due to the high degrees of medical complexity, managing comorbidities and multi-morbidities is especially difficult. A patient with heart failure who also requires infusion therapy for cancer poses a problem with timing the administration of the diuretics because the patient must travel to the infusion facility. Home-based care services may develop into a potent catalyst for raising standards of care, enhancing patient satisfaction, and cutting expenses. While there are obvious and distinct benefits for patients and carers with complex and rare diseases, there are also advantages for larger patient populations with more widespread conditions who may face difficulties due to the complexity of their therapy or the effects of comorbidities and multidisease.
What Questions Should You Ask before Buying a Market Research Report?
- How is the rare diseases market evolving?
- What is driving and restraining the rare diseases market?
- How will each rare diseases submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each rare diseases submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading rare diseases markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the rare diseases projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of
Rare diseases projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the rare diseases market?
- Where is the rare diseases market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the rare diseases market today, and over the next 10 years:
- Our 290-page report provides 107 tables and 186 charts/graphs exclusively to you
- The report highlights key lucrative areas in the industry so you can target them - NOW
- It contains in-depth analysis of global, regional and national sales and growth
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the rare diseases market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
- You will find original analyses, with business outlooks and developments
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
Segments Covered in the Report:
Diseases
- Cancer
- Metabolic Diseases
- Neurological Conditions
- Hematologic Disorders
- Infectious Diseases
- Musculoskeletal Disorders
- Cardiovascular Disorders
- Others
Type
End-users
- Specialty Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Age
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:
North America
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2023 to 2033, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth:
- AbbVie Inc
- Alexion Pharmaceuticals, Inc. (AstraZeneca)
- Amgen Inc
- Biogen Inc
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson Services, Inc.
|
- Merck & Co Inc
- Novartis AG
- Pfizer Inc
- Sanofi S.A
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
|
Overall world revenue for Rare Diseases Market, 2023 to 2033 in terms of value the market will surpass US$205.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Rare Diseases Market, 2023 to 2033 report help you?
In summary, our 290-page report provides you with the following knowledge:
- Revenue forecasts to 2033 for Rare Diseases Market, 2023 to 2033 Market, with forecasts for diseases, type, end-users, and age, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Rare Diseases Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 13 of the major companies involved in the Rare Diseases Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Rare Diseases Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.
Table of Contents
1 Report Overview
- 1.1 Objectives of the Study
- 1.2 Introduction to Rare Diseases Market
- 1.3 What This Report Delivers
- 1.4 Why You Should Read This Report
- 1.5 Key Questions Answered by This Analytical Report Include:
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.7.1 Market Definitions
- 1.7.2 Market Evaluation & Forecasting Methodology
- 1.7.3 Data Validation
- 1.7.3.1 Primary Research
- 1.7.3.2 Secondary Research
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Reports
- 1.10 About
2 Executive Summary
3 Market Overview
- 3.1 Key Findings
- 3.2 Market Dynamics
- 3.2.1 Market Driving Factors
- 3.2.1.1 Increasing Number of Approval Driving Market Growth
- 3.2.1.2 Robust Pipeline by Major Players
3.2.1.2.1 Pfizer Rare Disease Pipeline
3.2.1.2.2 Sanofi Genzyme Corporation Rare Disease Pipeline
3.2.1.2.3 Novo Nordisk Rare Disease Pipeline
- 3.2.1.3 Increasing Awareness
- 3.2.2 Market Restraining Factors
- 3.2.2.1 High Research and Development Costs
- 3.2.2.2 High Entry Barriers to Challenge Market Growth
- 3.2.2.3 Physical Management of Patients Likely to Challenge Market Growth
- 3.2.3 Market Opportunities
- 3.2.3.1 Increasing Demand from Emerging Economies
- 3.2.3.2 Home-based Care Anticipated to Offer Lucrative Growth Prospects
- 3.2.3.3 Increasing Government Support
- 3.2.3.4 Rare Diseases Clinical Activity by Indication
- 3.3 COVID-19 Impact Analysis
- 3.4 Porter's Five Forces Analysis
- 3.4.1 Bargaining Power of Buyers (Low)
- 3.4.2 Bargaining Power of Suppliers (medium)
- 3.4.3 Threat of Substitutes (Low)
- 3.4.4 Threat of New Entrants (Low)
- 3.4.5 Industry Rivalry (High)
4 Rare Diseases Market Analysis by Diseases
- 4.1 Key Findings
- 4.2 Diseases Segment: Market Attractiveness Index
- 4.3 Rare Diseases Market Size Estimation and Forecast by Diseases
- 4.4 Cancer
- 4.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.4.2 Market Share by Region, 2023 & 2033 (%)
- 4.5 Metabolic Diseases
- 4.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.5.2 Market Share by Region, 2023 & 2033 (%)
- 4.6 Neurological Conditions
- 4.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.6.2 Market Share by Region, 2023 & 2033 (%)
- 4.7 Hematologic Disorders
- 4.7.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.7.2 Market Share by Region, 2023 & 2033 (%)
- 4.8 Infectious Diseases
- 4.8.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.8.2 Market Share by Region, 2023 & 2033 (%)
- 4.9 Musculoskeletal Disorders
- 4.9.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.9.2 Market Share by Region, 2023 & 2033 (%)
- 4.10 Cardiovascular Disorders
- 4.10.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.10.2 Market Share by Region, 2023 & 2033 (%)
- 4.11 Others
- 4.11.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 4.11.2 Market Share by Region, 2023 & 2033 (%)
5 Rare Diseases Market Analysis by Type
- 5.1 Key Findings
- 5.2 Type Segment: Market Attractiveness Index
- 5.3 Rare Diseases Market Size Estimation and Forecast by Type
- 5.4 Non-biologics
- 5.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 5.4.2 Market Share by Region, 2023 & 2033 (%)
- 5.5 Biologics
- 5.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 5.5.2 Market Share by Region, 2023 & 2033 (%)
6 Rare Diseases Market Analysis by End-users
- 6.1 Key Findings
- 6.2 End-users Segment: Market Attractiveness Index
- 6.3 Rare Diseases Market Size Estimation and Forecast by End-users
- 6.4 Specialty Pharmacies
- 6.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 6.4.2 Market Share by Region, 2023 & 2033 (%)
- 6.5 Hospital Pharmacies
- 6.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 6.5.2 Market Share by Region, 2023 & 2033 (%)
- 6.6 Retail Pharmacies
- 6.6.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 6.6.2 Market Share by Region, 2023 & 2033 (%)
7 Rare Diseases Market Analysis by Age
- 7.1 Key Findings
- 7.2 Age Segment: Market Attractiveness Index
- 7.3 Rare Diseases Market Size Estimation and Forecast by Age
- 7.4 Adult
- 7.4.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 7.4.2 Market Share by Region, 2023 & 2033 (%)
- 7.5 Pediatric
- 7.5.1 Market Forecast by Region, 2023-2033 (US$ bn)
- 7.5.2 Market Share by Region, 2023 & 2033 (%)
8 Rare Diseases Market Analysis by Region
- 8.1 Key Findings
- 8.2 Regional Market Size Estimation and Forecast
9 North America Rare Diseases Market Analysis
- 9.1 Key Findings
- 9.2 North America Rare Diseases Market Attractiveness Index
- 9.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
- 9.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
- 9.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
- 9.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
- 9.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
- 9.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
- 9.9 U.S. Rare Diseases Market Analysis
- 9.10 Canada Rare Diseases Market Analysis
10 Europe Rare Diseases Market Analysis
- 10.1 Key Findings
- 10.2 Europe Rare Diseases Market Attractiveness Index
- 10.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
- 10.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
- 10.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
- 10.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
- 10.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
- 10.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
- 10.9 Germany Rare Diseases Market Analysis
- 10.10 UK Rare Diseases Market Analysis
- 10.11 France Rare Diseases Market Analysis
- 10.12 Italy Rare Diseases Market Analysis
- 10.13 Spain Rare Diseases Market Analysis
- 10.14 Russia Rare Diseases Market Analysis
- 10.15 Rest of Europe Rare Diseases Market Analysis
11 Asia Pacific Rare Diseases Market Analysis
- 11.1 Key Findings
- 11.2 Asia Pacific Rare Diseases Market Attractiveness Index
- 11.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
- 11.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
- 11.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
- 11.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
- 11.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
- 11.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
- 11.9 Japan Rare Diseases Market Analysis
- 11.10 China Rare Diseases Market Analysis
- 11.11 India Rare Diseases Market Analysis
- 11.12 Australia Rare Diseases Market Analysis
- 11.13 South Korea Rare Diseases Market Analysis
- 11.14 Rest of Asia Pacific Rare Diseases Market Analysis
12 Latin America Rare Diseases Market Analysis
- 12.1 Key Findings
- 12.2 Latin America Rare Diseases Market Attractiveness Index
- 12.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
- 12.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
- 12.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
- 12.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
- 12.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
- 12.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
- 12.9 Brazil Rare Diseases Market Analysis
- 12.10 Mexico Rare Diseases Market Analysis
- 12.11 Rest of Latin America Rare Diseases Market Analysis
13 MEA Rare Diseases Market Analysis
- 13.1 Key Findings
- 13.2 MEA Rare Diseases Market Attractiveness Index
- 13.3 Market Size by Country, 2023, 2028 & 2033 (US$ bn)
- 13.4 Market Size Estimation and Forecast by Country, 2023-2033 (US$ bn)
- 13.5 Market Size Estimation and Forecast by Diseases, 2023-2033 (US$ bn)
- 13.6 Market Size Estimation and Forecast by Type, 2023-2033 (US$ bn)
- 13.7 Market Size Estimation and Forecast by End-users, 2023-2033 (US$ bn)
- 13.8 Market Size Estimation and Forecast by Age, 2023-2033 (US$ bn)
- 13.9 GCC Rare Diseases Market Analysis
- 13.10 South Africa Rare Diseases Market Analysis
- 13.11 Rest of MEA Rare Diseases Market Analysis
14 Company Profiles
- 14.1 AbbVie Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Company Overview
- 14.1.3 Financial Analysis
- 14.1.3.1 Net Revenue, 2015-2022
- 14.1.3.2 Regional Market Shares, 2021
- 14.1.3.3 Gross Profit, 2015-2022
- 14.1.3.4 R&D, 2015-2022
- 14.1.4 Product Benchmarking
- 14.2 Alexion Pharmaceuticals, Inc. (AstraZeneca)
- 14.2.1 Company Snapshot
- 14.2.2 Company Overview
- 14.2.3 Product Benchmarking
- 14.2.4 Strategic Outlook
- 14.3 Amgen Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Company Overview
- 14.3.3 Financial Analysis
- 14.3.3.1 Net Revenue, 2015-2022
- 14.3.3.2 Regional Market Shares, 2022
- 14.3.3.3 Gross Profit, 2015-2022
- 14.3.3.4 R&D, 2015-2022
- 14.3.4 Product Benchmarking
- 14.3.5 Strategic Outlook
- 14.4 Biogen Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Company Overview
- 14.4.3 Financial Analysis
- 14.4.3.1 Net Revenue, 2015-2021
- 14.4.3.2 Gross Profit, 2015-2021
- 14.4.3.3 R&D, 2015-2021
- 14.4.4 Product Benchmarking
- 14.4.5 Strategic Outlook
- 14.5 F. Hoffmann-La Roche Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Company Overview
- 14.5.3 Financial Analysis
- 14.5.3.1 Net Revenue, 2015-2021
- 14.5.3.2 Gross Profit, 2015-2021
- 14.5.3.3 R&D, 2015-2021
- 14.5.4 Product Benchmarking
- 14.5.5 Strategic Outlook
- 14.6 Johnson & Johnson Services, Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Company Overview
- 14.6.3 Financial Analysis
- 14.6.3.1 Net Revenue, 2015-2022
- 14.6.3.2 Regional Market Shares, 2021
- 14.6.3.3 Gross Profit, 2015-2022
- 14.6.3.4 R&D, 2015-2022
- 14.6.4 Product Benchmarking
- 14.6.5 Strategic Outlook
- 14.7 Merck & Co Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Company Overview
- 14.7.3 Financial Analysis
- 14.7.3.1 Net Revenue, 2015-2022
- 14.7.3.2 Regional Market Shares, 2021
- 14.7.3.3 Gross Profit, 2015-2022
- 14.7.3.4 R&D, 2015-2022
- 14.7.4 Product Benchmarking
- 14.8 Novartis AG
- 14.8.1 Company Snapshot
- 14.8.2 Company Overview
- 14.8.3 Financial Analysis
- 14.8.3.1 Net Revenue, 2015-2022
- 14.8.3.2 Regional Market Shares, 2021
- 14.8.3.3 Gross Profit, 2015-2022
- 14.8.3.4 R&D, 2015-2022
- 14.8.4 Product Benchmarking
- 14.8.5 Strategic Outlook
- 14.9 Pfizer Inc.
- 14.9.1 Company Snapshot
- 14.9.2 Company Overview
- 14.9.3 Financial Analysis
- 14.9.3.1 Net Revenue, 2015-2022
- 14.9.3.2 Regional Market Shares, 2021
- 14.9.3.3 Gross Profit, 2015-2022
- 14.9.3.4 R&D, 2015-2022
- 14.9.4 Product Benchmarking
- 14.9.5 Strategic Outlook
- 14.10 Sanofi S.A.
- 14.10.1 Company Snapshot
- 14.10.2 Company Overview
- 14.10.3 Financial Analysis
- 14.10.3.1 Net Revenue, 2015-2022
- 14.10.3.2 Regional Market Shares, 2021
- 14.10.3.3 Gross Profit, 2015-2022
- 14.10.3.4 R&D, 2015-2022
- 14.10.4 Product Benchmarking
- 14.11 Takeda Pharmaceuticals
- 14.11.1 Company Snapshot
- 14.11.2 Company Overview
- 14.11.3 Financial Analysis
- 14.11.3.1 Net Revenue, 2015-2022
- 14.11.3.2 Gross Profit, 2015-2022
- 14.11.3.3 R&D, 2015-2022
- 14.11.4 Product Benchmarking
- 14.11.5 Strategic Outlook
- 14.12 Teva Pharmaceuticals
- 14.12.1 Company Snapshot
- 14.12.2 Company Overview
- 14.12.3 Financial Analysis
- 14.12.3.1 Net Revenue, 2015-2021
- 14.12.3.2 Regional Market Shares, 2021
- 14.12.3.3 Gross Profit, 2015-2021
- 14.12.3.4 R&D, 2015-2021
- 14.12.4 Product Benchmarking
- 14.12.5 Strategic Outlook
- 14.13 Bristol-Myers Squibb Company
- 14.13.1 Company Snapshot
- 14.13.2 Company Overview
- 14.13.3 Financial Analysis
- 14.13.3.1 Net Revenue, 2015-2022
- 14.13.3.2 Gross Profit, 2015-2022
- 14.13.3.3 R&D, 2015-2022
- 14.13.4 Product Benchmarking
- 14.13.5 Strategic Outlook
15 Conclusion and Recommendations
- 15.1 Concluding Remarks
- 15.2 Recommendations for Market Players